Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for t
Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales.
Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient dea
Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), th
NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.